Literature DB >> 22902459

[A case of unresectable hilar cholangiocarcinoma successfully treated by gemcitabine and S-1 combination chemotherapy].

Seiichiro Tada1, Takahisa Fujikawa, Akira Tanaka, Toshihiro Abe, Yasunori Yoshimoto, Hisatsugu Maekawa, Norihiro Shimoike, Hironori Tanaka, Takashi Kawashima, Kei Shiraishi.   

Abstract

A 52-year-old male was presented with obstructive jaundice and liver dysfunction. He was diagnosed as hilar cholangiocarcinoma involving the confluence of the right and left hepatic duct and bifurcation of the main portal vein trunk. Swollen lymph nodes in the hepatoduodenal ligament were also detected. ERBD tubes were placed in each B2, 3, and 5 branch. GEM and S-1 combination chemotherapy was carried out for four months. As a reduction in the primary tumor and lymph nodes was observed on CT scan surgical exploration was conducted, and an extended left hepatectomy with partial resection of the portal vein and regional lymph node dissection was achieved. The postoperative course was uneventful, and the patient remained free of recurrence, 34 months after the original diagnosis was made, and 29 months after surgical resection. Thus, GEM and S-1 combination chemotherapy is one of the options for the management of advanced hilar cholangiocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22902459

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  3 in total

1.  Conversion surgery for initially unresectable extrahepatic biliary tract cancer.

Authors:  Moon Young Oh; Hongbeom Kim; Yoo Jin Choi; Yoonhyeong Byun; Youngmin Han; Jae Seung Kang; Heeju Sohn; Jung Min Lee; Wooil Kwon; Jin-Young Jang
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2021-08-31

Review 2.  Multimodal treatment strategies for advanced hilar cholangiocarcinoma.

Authors:  Matthew J Weiss; David Cosgrove; Joseph M Herman; Neda Rastegar; Ihab Kamel; Timothy M Pawlik
Journal:  Langenbecks Arch Surg       Date:  2014-06-25       Impact factor: 3.445

Review 3.  Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: a systematic review.

Authors:  Jan Grendar; Petra Grendarova; Richie Sinha; Elijah Dixon
Journal:  HPB (Oxford)       Date:  2013-08-26       Impact factor: 3.647

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.